Last reviewed · How we verify
GI198745
At a glance
| Generic name | GI198745 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects (PHASE1)
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Dutasteride in Patients With Low-grade Non-muscle Invasive Bladder Cancer (PHASE2)
- Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP
- Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression (NA)
- Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia (PHASE1)
- Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GI198745 CI brief — competitive landscape report
- GI198745 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI